Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Bi-Functionalized Aminoguanidine-Pegylated Periodic Mesoporous Organosilica Nanoparticles: A Promising Nanocarrier for Delivery of Cas9-Sgrna Ribonucleoproteine Publisher Pubmed



Salekdeh PR1 ; Mamani L2 ; Tavakkolybazzaz J1 ; Mousavi H1 ; Modarressi MH1 ; Salekdeh GH3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Nanotechnology, Agricultural Biotechnology Research Institute of Iran (ABRII), Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran
  3. 3. Department of Systems and Synthetic Biology, Agricultural Biotechnology Research Institute of Iran (ABRII), Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran
  4. 4. Department of Molecular Sciences, Macquarie University, Sydney, NSW, Australia

Source: Journal of Nanobiotechnology Published:2021


Abstract

Background: There is a great interest in the efficient intracellular delivery of Cas9-sgRNA ribonucleoprotein complex (RNP) and its possible applications for in vivo CRISPR-based gene editing. In this study, a nanoporous mediated gene-editing approach has been successfully performed using a bi-functionalized aminoguanidine-PEGylated periodic mesoporous organosilica (PMO) nanoparticles (RNP@AGu@PEG1500-PMO) as a potent and biocompatible nanocarrier for RNP delivery. Results: The bi-functionalized MSN-based nanomaterials have been fully characterized using electron microscopy (TEM and SEM), nitrogen adsorption measurements, thermogravimetric analysis (TGA), X-ray powder diffraction (XRD), Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR), and dynamic light scattering (DLS). The results confirm that AGu@PEG1500-PMO can be applied for gene-editing with an efficiency of about 40% as measured by GFP gene knockdown of HT1080-GFP cells with no notable change in the morphology of the cells. Conclusions: Due to the high stability and biocompatibility, simple synthesis, and cost-effectiveness, the developed bi-functionalized PMO-based nano-network introduces a tailored nanocarrier that has remarkable potential as a promising trajectory for biomedical and RNP delivery applications. [Figure not available: see fulltext.] © 2021, The Author(s).
Other Related Docs
12. The Crispr Growth Spurt: From Bench to Clinic on Versatile Small Rnas, Journal of Microbiology and Biotechnology (2017)
19. Crispr/Cas9 Revitalizes Adoptive T-Cell Therapy for Cancer Immunotherapy, Journal of Experimental and Clinical Cancer Research (2021)
24. Recent Advances in Gene Therapy and Modeling of Chronic Granulomatous Disease, Iranian Journal of Allergy# Asthma and Immunology (2019)
30. The Impact of Crispr-Cas System on Antiviral Therapy, Advanced Pharmaceutical Bulletin (2018)
31. Smart Internal Stimulus-Responsive Nanocarriers for Drug and Gene Delivery, Smart internal stimulus-responsive nanocarriers for drug and gene delivery (2015)